Omnipaque (iohexol) is a nonionic, low-osmolar contrast agent and is also available for oral use, offering gastrointestinal (GI) visualization with minimal side effects. Omnipaque has a neutral taste that even kids will drink.
Orally administered iohexol is poorly absorbed from the normal gastrointestinal tract. Omnipaque is well tolerated and absorbed if leakage into the peritoneal cavity occurs.
The recommended dosage of undiluted Omnipaque (at a concentration of for example 350 mg/mL) for computed tomography of the abdomen in adults is 500 mL to 1000 mL, diluted to concentrations of 6 mg/mL to 9 mg/mL. The oral dose should be administered about 20 to 40 minutes prior to the CT scan.

GE Healthcare is the result of the merger between GE Medical and Amersham Health in Nov. 2004, after GE acquired Amersham Health for 9.5 billion in Oct. 2003. Jeffrey R. Immelt, Chairman of the Board and Chief Executive of General Electric, said, 'Amersham's diagnostic pharmaceutical and life sciences business will add new, high growth platforms to GE Medical's diagnostic imaging, services and health care information technology businesses'. GE Healthcare, a UK company, is a unit of General Electric (NYSE: GE). GE Healthcare is a global leader in medical imaging, diagnostic imaging agents, interventional procedures, health care services, and information technology. For more than 100 years, health care providers have relied on GE Medical Systems, now GE Healthcare, for high quality medical technology and productivity solutions. GE Healthcare, headquartered now at the formerly seat of Amersham Healthcare in Great Britain, operates facilities around the world. Global Operations include organizations on the Americas, Europe, and Asia, including India, Japan, Korea China, Thailand and Vietnam.